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Background:  Anthracyclines and trastuzumab (Herceptin®) have led to significant improvements in breast cancer survival, but are 
associated with an increased risk of cardiotoxicity. Moreover, biomarker strategies to identify or predict which patients are at risk for 
cardiotoxicity remain poorly understood. Our objective was to determine if longitudinal changes in multiple biomarkers are associated with 
cardiotoxicity in breast cancer patients treated with these agents.
methods:  We evaluated longitudinal changes in eight biomarkers and cardiotoxicity in a multi-center cohort of 78 breast cancer patients 
undergoing doxorubicin and trastuzumab therapy at baseline and 3-month time intervals over a maximum follow-up time of 15 months. The 
following markers were measured: ultrasensitive troponinI (TnI), high-sensitivity C-reactive protein (CRP), N-terminal-prohormone of B-type 
natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15), myeloperoxidase (MPO), placental growth factor (PlGF), soluble 
fms-like tyrosine kinase receptor-1 (sFlt-1), and galectin-3 (gal-3). We determined if time-varying elevations in these biomarkers were 
associated with cardiotoxicity either at the same (diagnostic) or the subsequent 3-month visit (predictive). The outcome, cardiotoxicity, was 
defined at each visit as left ventricular ejection fraction recovered or declined.
results:  In our diagnostic model, GDF-15 (Hazard Ratio [HR] 1.71, 95% Confidence Interval (CI) 1.15-2.55, p=0.014), MPO (HR 1.38, 
95% CI 1.10-1.71, p=0.023), and PlGF (HR 3.78, 95% CI 1.30-11.0, p=0.047) were each associated with cardiotoxicity. Our prediction 
models showed very similar results with significant associations for GDF-15 (p=0.020) and MPO (p=0.003), and a marginally significant 
association for PlGF (p=0.075).
conclusion:  GDF-15, MPO, and PlGF appear relevant to diagnosing and predicting cardiotoxicity associated with doxorubicin and 
trastuzumab therapy. Validation of these findings is necessary before widespread application.
